Pleural tuberculosis : an update
PURPOSE OF REVIEW: Pleural tuberculosis accounts for fewer than 1% of all exudative effusions in western countries, occurring in only 3-5% of tuberculous patients. However, in developing countries like India, it is responsible for 30-80% of all pleural effusions encountered and may complicate tuberculosis in 31% of all cases. Thus, tuberculous pleuritis remains a major contributor to global morbidity and mortality. Tuberculous pleurisy presents a diagnostic and therapeutic problem due to the low sensitivity of the diagnostic tools. There have been many advances in the field that we have attempted to update.
RECENT FINDINGS: Due to the limitations of conventional tests and the delay of several weeks for mycobacterial culture results, there has been a resurgence of interest in newer rapid tests and biomarkers. This review highlights the deficiencies of the traditional tests, while providing an overview of the newer tests. In addition, we provide an update on the changing epidemiology, clinical features and current treatment options.
SUMMARY: Newer immunological tests and scoring systems will revolutionize the way tuberculous pleurisy is diagnosed in the years ahead. Future research needs include validating the available diagnostic tests in larger randomized studies, finding newer specific biomarkers that are simple, accurate and cost-effective for the developing world and determining treatment regimens specific for tuberculous pleurisy.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2010 |
---|---|
Erschienen: |
2010 |
Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
---|---|
Enthalten in: |
Current opinion in pulmonary medicine - 16(2010), 4 vom: 15. Juli, Seite 399-406 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Udwadia, Zarir F [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 28.09.2010 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
---|
doi: |
10.1097/MCP.0b013e328339cf6e |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM198656505 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM198656505 | ||
003 | DE-627 | ||
005 | 20231223213135.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231223s2010 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/MCP.0b013e328339cf6e |2 doi | |
028 | 5 | 2 | |a pubmed24n0662.xml |
035 | |a (DE-627)NLM198656505 | ||
035 | |a (NLM)20531085 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Udwadia, Zarir F |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pleural tuberculosis |b an update |
264 | 1 | |c 2010 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.09.2010 | ||
500 | |a Date Revised 19.11.2015 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a PURPOSE OF REVIEW: Pleural tuberculosis accounts for fewer than 1% of all exudative effusions in western countries, occurring in only 3-5% of tuberculous patients. However, in developing countries like India, it is responsible for 30-80% of all pleural effusions encountered and may complicate tuberculosis in 31% of all cases. Thus, tuberculous pleuritis remains a major contributor to global morbidity and mortality. Tuberculous pleurisy presents a diagnostic and therapeutic problem due to the low sensitivity of the diagnostic tools. There have been many advances in the field that we have attempted to update | ||
520 | |a RECENT FINDINGS: Due to the limitations of conventional tests and the delay of several weeks for mycobacterial culture results, there has been a resurgence of interest in newer rapid tests and biomarkers. This review highlights the deficiencies of the traditional tests, while providing an overview of the newer tests. In addition, we provide an update on the changing epidemiology, clinical features and current treatment options | ||
520 | |a SUMMARY: Newer immunological tests and scoring systems will revolutionize the way tuberculous pleurisy is diagnosed in the years ahead. Future research needs include validating the available diagnostic tests in larger randomized studies, finding newer specific biomarkers that are simple, accurate and cost-effective for the developing world and determining treatment regimens specific for tuberculous pleurisy | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 7 | |a Biomarkers |2 NLM | |
700 | 1 | |a Sen, Tiyas |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current opinion in pulmonary medicine |d 1995 |g 16(2010), 4 vom: 15. Juli, Seite 399-406 |w (DE-627)NLM090955196 |x 1531-6971 |7 nnns |
773 | 1 | 8 | |g volume:16 |g year:2010 |g number:4 |g day:15 |g month:07 |g pages:399-406 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/MCP.0b013e328339cf6e |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 16 |j 2010 |e 4 |b 15 |c 07 |h 399-406 |